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Role of C-Reactive Protein at Sites  
of inflammation and infection
Nicola R. Sproston and Jason J. Ashworth*
School of Healthcare Science, Manchester Metropolitan University, Manchester, United Kingdom
C-reactive protein (CRP) is an acute inflammatory protein that increases up to 1,000-fold 
at sites of infection or inflammation. CRP is produced as a homopentameric protein, 
termed native CRP (nCRP), which can irreversibly dissociate at sites of inflammation and 
infection into five separate monomers, termed monomeric CRP (mCRP). CRP is syn-
thesized primarily in liver hepatocytes but also by smooth muscle cells, macrophages, 
endothelial cells, lymphocytes, and adipocytes. Evidence suggests that estrogen in the 
form of hormone replacement therapy influences CRP levels in the elderly. Having been 
traditionally utilized as a marker of infection and cardiovascular events, there is now 
growing evidence that CRP plays important roles in inflammatory processes and host 
responses to infection including the complement pathway, apoptosis, phagocytosis, 
nitric oxide (NO) release, and the production of cytokines, particularly interleukin-6 and 
tumor necrosis factor-α. Unlike more recent publications, the findings of early work 
on CRP can seem somewhat unclear and at times conflicting since it was often not 
specified which particular CRP isoform was measured or utilized in experiments and 
whether responses attributed to nCRP were in fact possibly due to dissociation into 
mCRP or lipopolysaccharide contamination. In addition, since antibodies for mCRP are 
not commercially available, few laboratories are able to conduct studies investigating 
the mCRP isoform. Despite these issues and the fact that most CRP research to date 
has focused on vascular disorders, there is mounting evidence that CRP isoforms have 
distinct biological properties, with nCRP often exhibiting more anti-inflammatory activi-
ties compared to mCRP. The nCRP isoform activates the classical complement pathway, 
induces phagocytosis, and promotes apoptosis. On the other hand, mCRP promotes 
the chemotaxis and recruitment of circulating leukocytes to areas of inflammation and 
can delay apoptosis. The nCRP and mCRP isoforms work in opposing directions to 
inhibit and induce NO production, respectively. In terms of pro-inflammatory cytokine 
production, mCRP increases interleukin-8 and monocyte chemoattractant protein-1 
production, whereas nCRP has no detectable effect on their levels. Further studies are 
needed to expand on these emerging findings and to fully characterize the differential 
roles that each CRP isoform plays at sites of local inflammation and infection.
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C-ReACTive PROTeiN (CRP)
C-reactive protein is a homopentameric acute-phase inflammatory protein, a highly conserved 
plasma protein that was initially discovered in 1930 by Tillet and Francis while investigating the 
sera of patients suffering from the acute stage of Pneumococcus infection and was named for its 
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reaction with the capsular (C)-polysaccharide of Pneumococcus 
(1). In the presence of calcium, CRP binds to polysaccharides 
such as phosphocholine (PCh) on microorganisms and triggers 
the classical complement pathway of innate immunity by activat-
ing C1q (2). CRP has many homologs in vertebrates and some 
invertebrates (3) and is a member of the pentraxin family, which 
includes other structurally related molecules such as serum 
amyloid A (4). Transcriptional induction of the CRP gene mainly 
occurs in hepatocytes in the liver in response to increased levels of 
inflammatory cytokines, especially interleukin-6 (IL-6) (5).
C-reactive protein exhibits elevated expression during inflam-
matory conditions such as rheumatoid arthritis, some cardio-
vascular diseases, and infection (6). As an acute-phase protein, 
the plasma concentration of CRP deviates by at least 25% during 
inflammatory disorders (7). The highest concentrations of CRP 
are found in serum, with some bacterial infections increasing 
levels up to 1,000-fold (8). However, when the stimuli ends, CRP 
values decrease exponentially over 18–20 h, close to the half-life 
of CRP (9). CRP plasma levels increase from around 1 µg/mL to 
over 500 µg/mL within 24–72 h of severe tissue damage such as 
trauma and progressive cancer (10). IL-6 is reported to be the 
main inducer of CRP gene expression, with IL-1 enhancing the 
effect (11). However, although IL-6 is necessary for CRP gene 
induction, it is not sufficient to achieve this alone (12).
There are many factors that can alter baseline CRP levels incl-
uding age, gender, smoking status, weight, lipid levels, and blood 
pressure (13). The average levels of CRP in serum in a healthy 
Caucasian is around 0.8 mg/L, but this baseline can vary greatly 
in individuals due to other factors, including polymorphisms in 
the CRP gene (14). The human CRP gene can be found at 1q23.2 
on the long arm of chromosome 1, and to date, there have been no 
allelic variations or genetic deficiencies discovered for this gene 
although some polymorphisms have been identified (13). For 
example, up to 50% of baseline variance in CRP is associated with 
the number of dinucleotide repeats found in an intronic region 
of the gene (15).
There is no significant seasonal variation in baseline CRP 
concentration; however, twin studies show a significant heritable 
component in baseline CRP values that is independent of age and 
body mass index (16). Pankow et  al. (17) found evidence that 
interindividual variation in blood CRP levels is 35–40% heritable. 
Increased CRP levels are typically associated with disease, but liver 
failure is one condition observed to impair CRP production. Very 
few drugs reduce elevated CRP levels unless they treat the under-
lying pathology that is causing the acute-phase stimulus (16).
There is emerging research that oral hormone replacement 
therapy (HRT) causes background levels of circulating CRP to 
increase in postmenopausal women, increasing the risk of throm-
botic events such as clots (18). Corcoran et al. (19) found that a 
combination of estrogen and oxidized low-density lipoproteins 
(oxLDLs) increased CRP expression in a model of coronary heart 
disease in both older men and postmenopausal women, but no 
effect on CRP expression was seen when estrogen supplementa-
tion was replaced with testosterone. Ridker et al. (20) found that 
healthy postmenopausal women had nearly twofold increased 
levels of circulating CRP when they were taking oral HRT and 
that CRP was the most affected inflammatory marker. Numerous 
studies have confirmed that CRP is a predictive marker for card-
iovascular disease and that HRT use in postmenopausal women 
increases the risk of stroke and blood clots (20–23).
Interestingly the mode of HRT delivery appears to influence 
the effect on circulating CRP levels. Vongpatanasin et  al. (23) 
found that estrogen administered orally increases circulating 
CRP levels twofold, whereas estrogen administered transdermally 
had no effect on circulating CRP levels. Similarly, patients taking 
oral HRT containing estrogens combined with progestogens had 
an increase in circulating CRP levels in the first 12  months of 
therapy compared to those using transdermal therapy who dem-
onstrated no change in circulating CRP levels (22). In contrast, 
several other studies have instead shown that circulating CRP 
levels are reduced in humans treated with transdermal estrogen 
(24, 25). A reduction in CRP levels following peripheral estrogen 
administration supports the findings of Ashcroft et  al. (26) 
demonstrating that estrogen reduces the inflammatory response 
during wound healing. The effect of transdermal administration 
of estrogen on local CRP levels in peripheral tissues such as skin 
has not yet been elucidated, with previous studies measuring only 
circulating levels of CRP.
iSOFORMS OF CRP
The pentameric protein, termed native CRP (nCRP), is character-
ized by a discoid configuration of five identical non-covalently 
bound subunits, each 206 amino acids long with a molecular 
mass of about 23 kDa. These five subunits lie in the same orienta-
tion around a central pore and arranged in a characteristic “lectin 
fold” with a two-layered beta sheet (15). Each subunit lies with 
the PCh binding site facing the “recognition” face of the nCRP 
molecule (27). The molecule has a ligand-binding face that has 
a characteristic feature of having two calcium ions per protomer. 
The calcium ions are important for the stability and binding of 
ligands. The “opposite” face interacts with the C1q aspect of the 
complement pathway as well as interacting with Fc receptors (6).
The pentameric protein is synthesized primarily in liver 
hepa tocytes but has also been reported to be synthesized in 
other cell types such as smooth muscle cells (28), macrophages 
(29), endothelial cells (30), lymphocytes, and adipocytes (31). 
CRP is first synthesized as monomers and then assembled into 
the pentamer in the endoplasmic reticulum of the source cell. 
In hepatocytes, the pentameric protein is retained in the endo-
plasmic reticulum by binding to two carboxylesterases, gp60a and 
gp50b (32). While in a resting (non-inflammatory) state, CRP is 
released slowly from the endoplasmic reticulum, but following 
an increase in inflammatory cytokine levels, the binding CRP to 
the carboxylesterases decreases and CRP is secreted rapidly (6). 
The stimulation of CRP synthesis mainly occurs in response to 
pro-inflammatory cytokines, most notably IL-6 and to a lesser 
degree IL-1 and tumor necrosis alpha (TNF-α) (33).
Pentameric CRP can be irreversibly dissociated, with the 
resu ltant free subunits termed monomeric (or modified) CRP 
(mCRP). The dissociation of nCRP into free subunits has been 
observed at either high concentrations of urea (34) or high tem-
peratures in the absence of calcium (35). The mCRP molecules are 
distinguished from nCRP by their different antigenic, biological, 
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and electrophoretic activities (36) and by the fact that they express 
different neoepitopes (37). The two isoforms of CRP have been 
shown to have distinct biological functions in the inflammatory 
process. For example, Khreiss et al. (37) provided evidence that 
nCRP suppresses the adherence of platelets to neutrophils, whereas 
mCRP enhances these interactions. This difference in function 
can be explained by the two isoforms binding to differing types 
of Fcgamma (Fcγ)-receptor involved in the signaling process. The 
mCRP isoform utilizes the low-affinity immune complex binding 
immunoglobulin G (IgG) receptor called FcγRIIIb (CD16b) on 
neutrophils and FcγRIIIa (CD16a) on monocytes, while nCRP 
binds to the low-affinity IgG receptor FcγRIIa (CD32) (38).
Evidence is emerging of new structural intermediates of 
CRP with biological function. Ji et al. (39) found that the native 
protein first dissociates into subunits while retaining some of 
the native conformation before fully dissociating into mCRP. 
This intermediate, termed mCRPm, is formed when the nCRP 
is bound to cell membranes and then dissociates, allowing the 
subunits to retain some of the conformation before fully dissoci-
ating into mCRP subunits on detachment from the membrane. 
It is suggested that this transitional process allows for more effec-
tive regulation of CRP function, with mCRPm allowing for the 
enhanced activation of the classical complement pathway (39). 
Further work needs to be conducted to determine the biological 
functions of the mCRPm intermediate, but initial findings suggest 
that it behaves in a similar manner to mCRP, typically promoting 
pro-inflammatory activity.
CRP iN DiSeASe PATHOLOGY
The majority of CRP research has focused on the role of CRP and 
its isoforms on cardiovascular disease and stroke. CRP is used 
as a clinical marker of inflammation, with elevated serum levels 
being a strong independent predictor of cardiovascular disease 
in asymptomatic individuals (40). CRP levels have been linked 
to prognosis in patients with atherosclerotic disease, congestive 
heart failure, atrial fibrillation, myocarditis, aortic valve disease, 
and heart transplantation, suggesting that it has an active role 
in the pathophysiology of cardiovascular disease (41). High-
sensitivity assays, such as nephelometric assays, are used to detect 
baseline levels of CRP and patients who are at risk of cardiovas-
cular disease. An individual with a CRP level higher than 3 mg/L 
has an increased risk of coronary heart disease (42), and this risk 
increases in those with type 2 diabetes (43).
Increased levels of CRP have been found in patients with 
appendicitis, cholecystitis, pancreatitis, and meningitis (44). 
In patients suffering possible symptoms of appendicitis, acute 
appe ndicitis can be excluded in those with CRP levels lower than 
25 mg/L in blood taken 12 h after the onset of symptoms (45). 
When clinical symptoms of cholecystitis occur concurrently with 
CRP levels of over 30 mg/L, an accurate diagnosis of cholecystitis 
can be obtained with 78% sensitivity, suggesting that CRP is a 
more sensitive marker than erythrocyte sedimentation rate 
and white cell count in supporting cholecystitis diagnosis (46). 
In terms of acute pancreatitis, CRP levels of more than 210 mg/L 
were able to discriminate between mild and severe cases, with 
83% sensitivity and 85% specificity (47). Serum CRP is elevated 
in bacterial meningitis, and resolution of symptoms following 
treatment with antibiotics is slow in those with the highest CRP 
levels (48). Measurement of CRP in cerebrospinal fluid has a 
sensitivity of 100% and a specificity of 94% for differentiating 
between patients with bacterial meningitis, viral meningitis, and 
no infection (49).
Although studies have shown that CRP levels increase during 
infections and inflammatory diseases, the precise role of CRP 
isoforms in their development and progression remains largely 
unknown. Thus, urgent investigations are required to determine 
the effects of each CRP isoform on specific cellular processes dur-
ing disease development. Evidence shows that in general nCRP 
tends to exhibit more anti-inflammatory activities relative to the 
mCRP isoform, possibly because nCRP limits the generation of 
the membrane attack complex (MAC) and C5a, thus inhibiting 
the alternative complement activation (50). In contrast, mCRP 
can have marked pro-inflammatory properties both in vitro and 
in vivo by promoting monocyte chemotaxis and the recruitment 
of circulating leukocytes to areas of inflammation via Fcy-RI and 
Fcy-RIIa signaling (50). Thus, in addition to therapeutic strate-
gies to inhibit CRP activity (51), more targeted therapies have 
been proposed for the treatment of CRP-mediated pathologies, 
including inhibiting mCRP activity (52) or preventing the dis-
sociation of nCRP into mCRP (53).
CRP AND iNFLAMMATiON
C-reactive protein levels are known to increase dramatically 
in response to injury, infection, and inflammation (Figure  1). 
CRP is mainly classed as an acute marker of inflammation, but 
research is starting to indicate important roles that CRP plays 
in inflammation. CRP is the principal downstream mediator of 
the acute-phase response following an inflammatory event and 
is primarily synthesized by IL-6-dependent hepatic biosynthesis 
(54, 55). The main role of CRP in inflammation tends to focus 
around the activation of the C1q molecule in the complement 
pathway leading to the opsonization of pathogens. Although CRP 
can initiate the fluid phase pathways of the host defense by acti-
vating the complement pathway, it can also initiate cell-mediated 
pathways by activating complement as well as to binding to Fc 
receptors of IgG (54). CRP binds to Fc receptors with the resulting 
interaction leading to the release of pro-inflammatory cytokines 
(56). CRP also has the ability to recognize self and foreign mol-
ecules based on the pattern recognition, something that other 
activators of complement such as IgG cannot achieve because 
these molecules only recognize distinct antigenic epitopes (56).
Evidence suggests that CRP is not only just a marker of 
inflammation but also plays an active role in the inflammatory 
process. However, most early research in the literature only refers 
to CRP and does not distinguish between the two isoforms. Thus, 
unlike more recent publications, the findings of early work on 
CRP can seem somewhat unclear and at times conflicting since 
it was often not specified which CRP isoform was measured or 
utilized in experiments, whether responses attributed to nCRP 
were in fact possibly due to partial/full dissociation into mCRP 
or if lipopolysaccharide (LPS) contamination could be present. 
More recent studies generally distinguish between the differential 
FiGuRe 1 | Summary of studies investigating the role of native C-reactive protein (CRP) and monomeric CRP in inflammation, infection, and disease.
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effects of each CRP isoform on inflammatory processes, but since 
antibodies for mCRP are not commercially available to date, few 
laboratories are able to conduct studies investigating the mCRP 
isoform.
There is increasing evidence that CRP has a functional role 
in the inflammatory process. It is well established that CRP is an 
acute marker of inflammation and that its concentration incre-
ases in circulation during inflammatory events. CRP is deposited 
at sites of inflammation and tissue damage in both naturally 
occurring and experimental conditions (57). However, there is 
a raft of published data investigating CRP that does not consider 
its two different isoforms. Understandably, when some of these 
studies were conducted, the existence of two CRP isoforms was 
not well established and available antibodies would have been 
raised against the pentameric nCRP alone. Another issue with 
published data is that CRP localization is often investigated in 
only a narrow range of inflammatory conditions and tissue types. 
Although the mCRP isoform has been shown to be insoluble in 
plasma, it becomes localized in inflamed tissues and amplifies a 
pro-inflammatory response by a positive feedback loop (58).
The literature suggests that CRP binds to damaged cell mem-
branes and contributes to the inflammatory response (59), with 
CRP molecules becoming associated with terminal complement 
complexes, especially in atherosclerotic lesions (60). Lagrand 
et al. (61) provided evidence that CRP localizes to infarcted heart 
tissue and promotes local complement activation, triggering fur-
ther damage to the heart tissue. Gitlin et al. (62) concluded that 
CRP was localized to the nuclei of cells within the synovium of 
rheumatoid arthritis patients, but the cell type was not identified 
at the time. However, other studies indicate no significant locali-
zation of CRP in a number of pathologies, suggesting that CRP 
is found predominantly in the fluid phase rather than becoming 
deposited in tissues at sites of inflammation or injury (63). There 
has been little research conducted on the localization of CRP in 
inflammatory cells to date. There is a correlation between the 
localization of CRP in neutrophil infiltrates, especially in lesions 
of vasculitis and allergic encephalomyelitis (64, 65).
CRP AND iNFeCTiON
C-reactive protein is a marker for inflammation, and its levels 
increase during bacterial infection (66). Kingsley and Jones (67) 
stated that CRP increases during infection in response to mono-
cytic mediators such as IL-1 and IL-6 and that it has a stable decay 
rate. It is thought that most of the interaction between CRP and 
the immune response to pathogens involves the binding of CRP 
to PCh and the activation of the classical complement pathway 
(68). Mold et al. (69) showed that CRP provides mice with protec-
tion against infection by the gram-positive pathogen Streptococcus 
pneumoniae by binding to a PCh determinant of the pathogen 
cell wall and activating the complement pathway. Mice pretreated 
with 200  µg CRP before being infected showed an increase in 
percentage survival across all pathogen doses tested. The study 
concluded that the ability of CRP to protect against infection lies 
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in its ability to bind to pneumococcal polysaccharide C in the 
bacterial cell wall (69).
Szalai et al. (70) showed that CRP can confer protective benefits 
against Salmonella enterica serovar Typhimurium, a gram-negative 
pathogen that provides a model of typhoid fever in mice. By using 
transgenic mice expressing human CRP, the study found that CRP 
offered protection against a low dose of Typhimurium and incre-
ased resistance to a fatal infection with a low dose of Typhimurium. 
Szalai et al. (70) concluded that CRP increases the early clearance 
of intravenously injected bacteria from the blood and reduces 
dissemination of bacteria to the liver and spleen during the initial 
stages of infection, thus allowing the mice to survive infection.
Marnell et al. (71) reviewed the protective role CRP against 
Haemophilus influenza infection in both transgenic and wild-
type mice treated by passive inoculation. CRP was shown to bind 
the pneumococcal C-polysaccharide of bacteria and opsonize 
them for phagocytosis. This process did not require the use of the 
Fcγ receptors, suggesting that CRP is not primarily protective by 
direct opsonization but more likely through activation of comple-
ment and subsequent opsonophagocytosis.
Kingsley and Jones (67) tested whether CRP could be used 
to distinguish different types of infections. They discovered that 
mean CRP levels in a spreading infection were higher than those 
in other colonized, critically colonized, and locally infected 
groups. All cases of infection showed an increase in CRP levels 
compared to non-infected controls, but CRP levels could not dis-
tinguish between the infection types, showing that it is infection 
in general that causes CRP levels to increase, rather than the type 
of infection. This was also noted by Healy and Freedman (66) who 
showed that CRP levels can be used only as a method of detecting 
infection, rather than distinguishing it.
C-reactive protein can mediate host responses to Staphyloc­
occus aureus including some protective function against infection 
and an increase in phagocytosis of this pathogen. Povoa et al. 
(72) stated that the normal CRP level for the healthy population 
is about 0.08 mg/dL, and this increases to more than 8.7 mg/dL 
during chronic S. aureus infection. Thus, CRP can be used as 
an indicator of infection, alongside a body temperature of more 
than 38.2°C. Patterson and Mora (73) observed that enhanced 
resistance to intraarticular infection with S. aureus in chickens 
was associated with an increase in serum CRP and that isolated 
preparations of the protein produced antibacterial activity. 
Mulholland and Cluff (74) discovered that endotoxin-induced 
changes in resistance to local infection with S. aureus in rabbits 
were correlated with the circulating levels of leukocytes in the 
blood. The study showed that induced resistance was paralleled 
by an increase in CRP and leukocytes. This was collaborated 
by Patterson et al. (75) who found an association between CRP 
and non-specific resistance to infection, including S. aureus and 
showed that CRP was acting upon the polysaccharide bacterial 
cell wall. Black et  al. (3) stated that CRP enhances the in vitro 
phagocytosis of many microorganisms (including S. aureus) by 
leukocytes. Their work confirmed this finding even in the absence 
of complement, suggesting that the enhancement of phagocytosis 
by CRP is due to the interactions with Fcγ receptors.
In summary, evidence shows that CRP is not only a marker 
of infection and inflammation but that CRP also has a protective 
role against bacterial infections (Figure 1), principally through 
the activation of complement and subsequent opsonization of 
pathogens.
CRP AND COMPLeMeNT
Complement is one of the major defenses of the human immune 
system that is involved in the clearance of foreign particles and 
organisms after recognition by antibody. The complement path-
way is made up of 35 plasma or membrane proteins that is an 
important system in immunity and the defense of the host against 
microbial infection. The components of the complement pathway 
can be activated in three different pathways to trigger a cascade of 
proteins, which are used to help bind microbial surfaces for the 
immune system to recognize and activate phagocytosis (76, 77). 
The classical pathway is triggered by a target bound antibody, 
whereas the lectin pathway is triggered by microbial repetitive 
polysaccharide structures and the alternative pathway is trig-
gered by recognition of other foreign surface structures. Even 
though the triggers are different, the three pathways merge at a 
pivotal activation of the C3 and C5 convertases. A majority of 
the components are synthesized in the liver, C1 in the intestinal 
epithelium, and factor D in the adipose tissue (76).
The role of CRP in activating the complement pathway has 
been extensively investigated. In 1974, Kaplan and Volanakis first 
described the ability of CRP to activate the classical comple ment 
pathway using C-polysaccharide and phospholipid ligands (59). 
The activation of complement by CRP is considered a crucial step 
since when complement was depleted, and the effects of CRP 
were abrogated (50).
The opposite face of the CRP molecule, which is typically com-
plexed with polyvalent ligand or chemically cross-linked, binds to 
C1q and activates the classical complement pathway (56). C1q is 
a large 460-kDa molecule made up of six identical subunits, each 
made up of three structurally similar but distinct polypeptide 
chains (78). This process requires the use of calcium ions for the 
stable formation of the C1 complex (79). CRP is most effective 
during the early classical pathway activation of C1, C4, and C2 
(80). This is because the ligand-bound interaction with C1q leads 
to the formation of C3 convertase, triggering the complement 
activation of C1–C4 but with little activation of the late comple-
ment proteins C5–C9 (15).
Activation of complement by CRP varies from activation by 
antibody in that CRP has selective activation of early components 
without the need to form the MAC. In addition to activating the 
classical complement pathway, CRP can inhibit the alternative 
complement pathway by decreasing C3 and C5 convertase activi-
ties and inhibiting the complement amplification loop. This is 
achieved by the recruitment of factor H to the cell surface and 
by preventing C5 convertase cleaving C5 to recruit neutrophils 
and prevent the formation of the MAC (71). As the levels of CRP 
increase, this causes decreased binding of C3b and C5b-9 to 
liposomes, possibly also explaining the lack of C5–C9 consump-
tion by CRP during classical pathway activation (80).
Both the initiator (C1q) and the inhibitor (C4bp) of the 
classic complement pathway compete for mCRP binding, with 
the competition controlling the local balance of activation and 
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inhibition of the pathway in tissues (58). Interestingly, mCRP but 
not nCRP binds the C4bp inhibitor, suggesting that mCRP rather 
than nCRP is able to provide a high degree of control over the 
classic complement pathway (58).
CRP AND APOPTOSiS
There has been little research conducted into the effect of CRP 
on the proliferation process. However, there is evidence that 
CRP has a major role in the apoptosis process. Devaraj et al. (81) 
showed that CRP stimulates the production of pro-apoptotic 
cytokines and inflammatory mediators via the activation of 
Fc-γ receptors. The pro-apoptotic cytokines and inflammatory 
mediators induced by CRP include interleukin-1β (IL-1β), tumor 
necrosis factor-α (TNFα), and reactive oxygen species (82, 83).
C-reactive protein induces the upregulation of p53 in mono-
cytes and affects cell cycle kinetics of monocytes through CD32 
(FcγRII), inducing apoptosis by G2/M arrest in the cell cycle (84). 
CD32 receptors have been shown to trigger apoptotic signals 
and are expressed in a subset of monocytes that polarize to pro-
inflammatory macrophages, suggesting that CRP may dampen 
macrophage-driven pro-inflammatory responses by inducing 
apoptosis (85).
C-reactive protein is elevated in cardiovascular disorders and 
is a mediator of atherosclerosis. CRP localizes directly in the 
atherosclerotic plaques where it induces the expression of genes 
that are directly involved in the adhesion of monocytes and the 
recruitment of intracellular molecules such as E-selectin and 
monocyte chemoattractant protein-1 (MCP-1). CRP has also 
been shown to play a role in mediating low-density lipoprotein 
uptake in macrophages and activating the complement system, 
which is implicated in atherogenesis (86). Apoptosis occurs in 
atherosclerotic plaques and the number of apoptotic cells increase 
as lesions become more advanced. As cells become apoptotic, 
they start to cause plaque disruption, leading to the expression of 
growth arrest- and DNA damage-inducible gene 153 (GADD153). 
GADD153 upregulation has been shown to induce G1 arrest or 
apoptosis in some cancer cell lines (87). Blaschke et al. (88) found 
that CRP can induce the apoptosis of human coronary vascular 
smooth muscle cells through a caspase-mediated mechanism, 
especially through increased caspase-3 activity. CRP was co-
localized to the GADD153 gene product in atherosclerotic lesions 
suggesting that CRP is triggering the caspase cascade and apopt-
osis by inducing the expression of the GADD153 gene.
There is little research on how the two isoforms of CRP inte-
ract with the apoptosis process. It is suggested that CRP can exert 
anti-apoptotic activity but only when the cyclic pentameric struc-
ture is lost. This would suggest that the apoptotic activity of CRP 
is induced through the native isoform. Native CRP (nCRP) can 
bind to low-affinity IgG FcγRIIa (CD32) and IgG FcγRI (CD64), 
leading to depressed functional activities, degranulation, and the 
generation of superoxide by inducible respiratory burst. On the 
other hand, mCRP binds to low-affinity IgG FcγRIIIb (CD16) 
that can delay apoptosis by triggering the cell survival pathway in 
neutrophils, even at low concentrations (89).
The nCRP isoform has the ability to opsonize apoptotic 
cells and induce the phagocytosis of damaged cells. Removal of 
nCRP-bound apoptotic monocytes and macrophages may be via 
FcγR-mediated phagocytosis (84). CRP binds to apoptotic cells, 
inhibits the assembly of terminal complement components, and 
promotes the opsonization of apoptotic cells (89, 90).
CRP AND NiTRiC OXiDe (NO)
C-reactive protein has the ability to attenuate NO production with 
a marked reduction in in vitro angiogenesis, cell migration, and 
capillary-like tube formation by CRP at concentrations known 
to cause cardiovascular risk (91). Eisenhardt et al. (15) showed 
that CRP upregulated the expression of adhesion molecules and 
inhibited endothelial nitric oxide synthase (eNOS) expression, 
indicating a role for CRP in the production of NO. Several stud-
ies have revealed that CRP inhibits NO production via down-
regulation of eNOS in cardiovascular endothelial cells, thereby 
inhibiting angiogenesis in vitro and promoting the pathogenesis 
of atherosclerotic vascular disease through vasoconstriction, leu-
kocyte adherence, and inflammation (14, 91–93). Another study 
found that it was in fact the nCRP isoform that downregulated 
eNOS and thus impaired endothelial function in ApoE knockout 
mice, via a mechanism thought to involve iNOS (94). Eisenhardt 
et al. (15) provided evidence that nCRP suppresses endothelium-
dependent NO-mediated dilation by activating the p38 mitogen-
activated protein kinase (MAP kinase) pathway and NADPH 
oxidase, suggesting that multiple pathways could be interacting 
with this process.
In contrast, mCRP has the opposite effect, enhancing NO 
production in neutrophils via upregulation of eNOS (95) with 
reverse transcription polymerase chain reaction showing an amp-
lification of eNOS mRNA, but not iNOS or nNOS mRNA. This 
study highlighted that mCRP initiates calcium (Ca2+) mobiliza-
tion and activation of calmodulin and PI3 kinase to induce NO 
formation in neutrophils (95). The effect of CRP isoforms on 
other inflammatory cells, such as monocytes or macrophages, 
has not been investigated to date.
CRP iSOFORMS AND iNFLAMMATORY 
CYTOKiNeS
There has been increasing evidence of a relationship between 
CRP and several pro-inflammatory cytokines.
iL-6 and CRP
Interleukin-6 is a pro-inflammatory cytokine secreted by vari-
ous cells including inflammatory cells, keratinocytes, fibroblasts, 
and endothelial cells. It regulates the acute-phase response, and 
its main role involves the host response to infection (96). Even 
though it is predominantly a pro-inflammatory cytokine, in 
some cells, IL-6 can have regenerative and anti-inflammatory 
effects through the activation of membrane-bound IL-6 receptor 
signaling (97).
Interleukin-6 is synthesized in the initial stages of inflamma-
tion and induces a number of acute-phase proteins, including 
CRP (98). IL-6 can also reduce the production of fibronectin, 
albumin, and transferrin as well as the promotion of CD4+ T 
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helper cells, which initiates the linking of innate and acquired 
immunity (98). There is a correlation between increasing levels 
of IL-6 during inflammation and increasing levels of CRP (11), 
with IL-6 inducing the CRP gene (12). However, most investiga-
tions of CRP production by IL-6 generally fail to indicate which 
isoforms of CRP are generated. In some cases, the antibodies 
used suggest that nCRP is present, but given IL-6 occurs at the 
sites of inflammation, the pentameric CRP may be dissociating 
into mCRP.
When CRP levels become elevated in atheroma, this leads to 
the induction of IL-6 by macrophages indicating that CRP may 
have a direct effect on IL-6 release (99). Krayem et al. (100) found 
that a combination of mCRP, nCRP, and oxLDL decreases IL-6 
production in a model of atherosclerosis. This triple combination 
suggests that nCRP might downregulate the IL-6 release by mac-
rophages that have been stimulated by both mCRP and oxLDL.
interleukin-8 (iL-8) and CRP
Interleukin-8 is a cytokine produced by numerous cell types 
including inflammatory cells, keratinocytes, fibroblasts, and 
endothelial cells. IL-8 acts as a potent chemoattractant of neutro-
phils (101) and is overexpressed in chronic inflammatory diseases 
and during septic shock (102). IL-8 stimulates the release of gran-
ules from neutrophils by a process called degranulation. These 
granules contain a range of antimicrobial effectors that can help 
combat infection (103). Neutrophils are the first inflammatory 
cells to arrive at the site of inflammation, and they carry out the 
phagocytosis of bacteria and release chemotactic mediators that 
recruit other leukocytes to the affected tissue (103).
Kibayashi et al. (104) indicated that CRP plays a role in athero-
sclerosis via enhanced IL-8 production and increased expres-
sion of IL-8 mRNA in a CRP dose-dependent manner. They 
showed that CRP promotes IL-8 production via the activation of 
the ERK, p38 MAPK, and JNK pathways. Conversely, Wigmore 
et  al. (105) indicated that IL-8 induces CRP production in 
hepatocytes, providing a potential feedback loop. The effect of the 
different CRP isoforms on IL-8 production has been investigated. 
Khreiss et al. (37) showed that nCRP had no detectable effect on 
the production of IL-8, whereas mCRP increased IL-8 production 
and IL-8 gene expression, promoting pro-inflammatory activity 
through a p38 MAPK-dependent mechanism. When treated with 
anti-CD16, there was inhibition of mCRP-stimulated NO forma-
tion and IL-8 release.
MCP-1 and CRP
Monocyte chemoattractant protein-1 is a cytokine that plays a 
role in the regulation of migration and infiltration of monocytes 
and macrophages (106). It is released by a number of cell types 
in response to events such as oxidative stress, cytokine release, 
and growth factor release (107). Human MCP-1 is known to 
bind to at least two receptors, and its production can be induced 
by interleukin-4 (IL-4), IL-1, TNF-α, bacterial LPS, and IFN-γ 
(107). There is increasing evidence that MCP-1 influences T-cell 
immunity by enhancing the secretion of IL-4 by T cells, as well 
as having a role in the migration of leukocytes (106). This in 
turn has a regulatory function on monocytes and macrophages, 
which are the major source of MCP-1 (107). MCP-1 is known 
to recruit monocytes to the vessel wall (99) and cause the arrest 
of rolling monocytes on endothelial monolayers that express 
E-selectin (108).
Evidence suggests that CRP stimulates endothelial cells to 
express MCP-1 (99) in addition to being a direct chemoat-
tractant of monocytes itself (109). CRP can promote monocyte 
chemotactic activity in response to MCP-1 via upregulation of 
the monocyte chemotaxis receptor CCR2, with elevated CRP 
levels promoting the accumulation of monocytes in the athero-
genic arterial wall (99). When vascular smooth muscle cells are 
exposed to increasing levels of CRP, MCP-1 mRNA substantially 
increased within 2 h and remained elevated for at least 24 h (110). 
Incubation with mCRP increases the secretion of MCP-1, leading 
to pro-inflammatory activity through a p38 MAPK-dependent 
mechanism, whereas nCRP had no detectable effect (37).
TNF-α and CRP
Tumor necrosis factor-α is a component of the acute-phase 
response and is mainly produced by monocytes and macrophages 
but can be produced by numerous other immune cells such as 
neutrophils, natural killer cells, and eosinophils. TNF-α is not 
usually detectable in a healthy host, but levels become elevated 
in a number of inflammatory and infectious conditions (111). 
The main stimulant of TNF-α production is LPS, but many other 
pathological conditions such as trauma infection, impaired wound 
healing, and heart failure also induce its production (111, 112). 
TNF-α mediates various processes such as cell proliferation, dif-
ferentiation, and apoptosis.
Studies have shown a correlation between TNF-α production 
and the concentration of CRP. TNF-α induces a dose-dependent 
secretion of CRP in hepatocytes, which corresponds to an increase 
in CRP mRNA (28). Conversely, elevated CRP levels in atheroma 
leads to the induction of IL-1β, IL-6, and TNF-α production by 
macrophages (99). Research shows a close relationship between 
TNF-α and IL-6 levels in inflammation (113), with both TNF-α 
and IL-6 inducing the transcription of CRP (33). However, there 
is some contradictory evidence showing a potential inhibitory 
effect of CRP on TNF-α production, suggesting that there could 
be a negative feedback mechanism whereby elevated levels of 
CRP inhibit further stimulation of CRP by reducing the TNF-α 
production (114). A combination of mCRP, nCRP, and oxLDL 
also causes a decrease in both TNF-α and IL-6 production in 
a macrophage model of atherosclerosis (100). This triple com-
bination suggests that nCRP might downregulate TNF-α and 
IL-6 production by macrophages stimulated by both mCRP 
and oxLDL.
CONCLuSiON
C-reactive protein is a homopentameric acute-phase inflamma-
tory protein that exhibits elevated expression during inflamma-
tory conditions such as rheumatoid arthritis, some cardiovascular 
diseases, and infection. Evidence suggests that CRP is an impor-
tant regulator of inflammatory processes and not just a marker of 
inflammation or infection. Key areas of inflammation and host 
responses to infection mediated by CRP include the comple-
ment pathway, apoptosis, phagocytosis, NO release, and cytokine 
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production. However, most research to date has investigated 
the role of CRP in the vascular tissues, highlighting the need to 
conduct further work to determine the precise role of CRP in 
peripheral tissues.
C-reactive protein is synthesized primarily in liver hepato-
cytes but also other cell types such as smooth muscle cells, 
macrophages, endothelial cells, lymphocytes, and adipocytes. 
Evidence also suggests that the sex steroid hormone estrogen can 
influence CRP levels, with HRT having a profound influence on 
CRP levels in the elderly. Administration of oral HRT increases 
background levels of CRP in circulation, whereas evidence sug-
gests that transdermal estrogen supplementation either reduces 
or has little effect on circulating CRP levels. A reduction in CRP 
levels following local administration of estrogen supports find-
ings showing that estrogen reduces the inflammatory response in 
peripheral tissues such as skin.
There are two distinct isoforms of CRP, nCRP and mCRP, and 
the nCRP isoform can irreversibly dissociate at sites of inflam-
mation, tissue damage, and infection into five mCRP subunits. 
Evidence indicates that nCRP often tends to exhibit more anti-
inflammatory activities compared to mCRP. The nCRP isoform 
activates the classical complement pathway, induces phagocytosis, 
and promotes apoptosis. On the other hand, mCRP promotes the 
chemotaxis and recruitment of circulating leukocytes to areas of 
inflammation and can delay apoptosis. The nCRP and mCRP 
isoforms inhibit and induce NO production via downregula-
tion and upregulation of eNOS, respectively. In terms of pro-
inflammatory cytokine production, mCRP increases IL-8 and 
MCP-1 production, whereas nCRP has no detectable effect on 
their levels. CRP can also induce IL-6 and TNF-α production at 
sites of inflammation, again suggesting probable involvement of 
mCRP from the dissociation of nCRP. Further studies are needed 
to expand on these emerging findings and to fully characterize 
the differential roles that each CRP isoform play at sites of local 
inflammation and infection.
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